BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38509351)

  • 1. The interplay between rheumatic diseases and pulmonary health.
    Fedorchenko Y; Zimba O; Yatsyshyn R; Doskaliuk B; Zaiats L; Fedorchenko M
    Rheumatol Int; 2024 Jul; 44(7):1179-1184. PubMed ID: 38509351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.
    Dai Y; Wang W; Yu Y; Hu S
    Clin Rheumatol; 2021 Apr; 40(4):1211-1220. PubMed ID: 32794076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
    Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
    Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management issues in rheumatoid arthritis-associated interstitial lung disease.
    England BR; Hershberger D
    Curr Opin Rheumatol; 2020 May; 32(3):255-263. PubMed ID: 32141954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.
    Dong R; Sun Y; Xu W; Xiang W; Li M; Yang Q; Zhu L; Ma Z
    Front Immunol; 2023; 14():1197458. PubMed ID: 37539050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.
    Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Atienza-Mateo B; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Mora-Gil MS; Portilla V; Corrales A; Blanco R; Cifrián JM; González-Gay MA; López-Mejías R
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.
    Chen J; Chi S; Li F; Yang J; Cho WC; Liu X
    Expert Opin Biol Ther; 2017 Mar; 17(3):265-283. PubMed ID: 28117616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
    Xie M; Zhu C; Ye Y
    BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.
    De Zorzi E; Spagnolo P; Cocconcelli E; Balestro E; Iaccarino L; Gatto M; Benvenuti F; Bernardinello N; Doria A; Maher TM; Zanatta E
    Clin Rev Allergy Immunol; 2022 Dec; 63(3):472-489. PubMed ID: 35303257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
    Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A
    Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
    Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
    Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.
    Jeong E; Hong H; Lee YA; Kim KS
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
    Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
    Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulmonary involvement in rheumatoid arthritis].
    Krause A; Rubbert-Roth A
    Z Rheumatol; 2019 Apr; 78(3):228-235. PubMed ID: 30887119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease.
    Castellanos-Moreira R; Rodríguez-García SC; Gomara MJ; Ruiz-Esquide V; Cuervo A; Casafont-Solé I; Ramírez J; Holgado S; Gómez-Puerta JA; Cañete JD; Haro I; Sanmarti R
    Ann Rheum Dis; 2020 May; 79(5):587-594. PubMed ID: 32156708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
    Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
    Front Immunol; 2021; 12():595811. PubMed ID: 33859634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development.
    Karakontaki FV; Panselinas ES; Polychronopoulos VS; Tzioufas AG
    Autoimmun Rev; 2021 Feb; 20(2):102742. PubMed ID: 33333235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.